Webcast Alert: ADVENTRX Pharmaceuticals, Inc. Announces LHA Life Sciences & Med Tech Day 2010 Presentation

July 14, 2010

NEW YORK, July 14 /PRNewswire-FirstCall/ — ADVENTRX Pharmaceuticals, Inc. (ANX) announces the following Webcast:

                   LHA Life Sciences & Med Tech Day 2010
    What:          Presentation

    When:         July 20, 2010 @ 10:00 AM Eastern


    Where:         ClientPage.asp?ID=160318

                   Live over the Internet --Simply log on to the
    How:           web at the address above.

    Contact:      Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=160318 or http://www.investorcalendar.com/

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) is a specialty pharmaceutical company whose product candidates are designed to improve upon existing cancer treatments by addressing limitations associated with their safety and use. Its lead product candidates include ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®), to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin and advanced or metastatic breast cancer; and ANX-514, a detergent-free emulsion formulation of the chemotherapy drug docetaxel (Taxotere®) for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The Company expects to file an NDA for ANX-530 in the fourth quarter of 2010. Additional information regarding ADVENTRX is available at www.adventrx.com

SOURCE ADVENTRX Pharmaceuticals, Inc.

Source: newswire

comments powered by Disqus